Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

1.17
-0.0300-2.50%
Post-market: 1.170.00000.00%19:55 EDT
Volume:2.15M
Turnover:2.55M
Market Cap:231.89M
PE:-1.45
High:1.22
Open:1.18
Low:1.16
Close:1.20
Loading ...

Esperion initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
17 Dec 2024

Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
14 Dec 2024

Esperion Swaps New Notes, Cash for $210 Million of Convertible Debt; Shares Slump Pre-Bell

MT Newswires Live
·
13 Dec 2024

BRIEF-Esperion Announces $210 Mln Convertible Debt Financing

Reuters
·
13 Dec 2024

Esperion Announces $210 Million Convertible Debt Financing

THOMSON REUTERS
·
13 Dec 2024

Esperion Therapeutics -Pursuant to Agreements, Co to Issue $100 Mln of 5.75% Convertible Notes Due 2030

THOMSON REUTERS
·
13 Dec 2024

Press Release: Esperion Announces $210 Million Convertible Debt Financing

Dow Jones
·
13 Dec 2024

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Dec 2024

Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel

MT Newswires Live
·
12 Dec 2024

Esperion entered into licensing agreement with Neopharm Israel

TIPRANKS
·
12 Dec 2024

BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel

Reuters
·
12 Dec 2024

Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel

THOMSON REUTERS
·
12 Dec 2024

Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments

THOMSON REUTERS
·
12 Dec 2024

Esperion selloff continues following competitor data from NewAmsterdam

TIPRANKS
·
12 Dec 2024